Therapeutic effect of Nigella sativa in patients of poor glycemic control

Asian Journal of Pharmaceutical and Clinical Research

Volumn 5, Issue SUPPL. 3, 2012, Pages 224-228

  Najmi, Ahmad ^a   Nasiruddin, Mohammad ^b   Khan, Rahat Ali ^b   Haque, Shahzad F ^b  

^a Index Medical College   (India)

^b ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Glycated hemoglobin (HbA1C); Nigella sativa; Poor glycemic control

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; GLUCOSE; HEMOGLOBIN A1C; HERBACEOUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLACK CUMIN; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DRUG CAPSULE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; PLANT SEED; POWDER; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VENOUS BLOOD;

EID: 84874704822     PISSN: 09742441     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Gilani, A.H., Q. Jabeen and M.A.U. Khan, 2004. A review of medicinal uses and pharmacological activities of Nigella sativa. Pak. J. Biol. Sci., 7: 441-451
2. Badary OA, Abdel-Naim AB, Abdel-Wahab MH, Hamada FM. (2000); The influence of thymoquinone on doxorubicin-induced hyperlipidemic nephropathy in rats. Toxicology, 2000; March 7; 143(3): 219-226.: Department of Pharmacology and Toxicology, College of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt.
3. Al-Ghamdi MS; The anti-inflammatory, analgesic and antipyretic activity of Nigella sativa. J. Ethnopharmacol. 2001 Jun; 76(1):45-8.
4. Al-Awadi F, Fatania H, Shamte U.; The effect of a plants mixture extract on liver gluconeogenesis in streptozosin induced diabetic rats.; Diabetes Res. 1991 Dec;18(4):163-8.
5. El, Tahir. K. E. H., M. M. S. Ashour, et al. (1993). The cardiovascular actions of the volatile oil of the Black Seed (Nigella sativa) in rats: Elucidation of the mechanism of action. General Pharmacology 24(5): 1123-1131.: Dep. Pharmacol., College Pharmacy, King Saud University, PO box 2457, Riyadh 11451, Saudi Arabia.
6. Zaoui A, Cherrah Y, Alaoui K, Mahassine N, Amarouch H, Hassar M. Effects of Nigella sativa fixed oil on blood homeostasis in rat.; J. Ethnopharmacol. 2002 Jan; 79 (1): 23-6 (U.K. Prospective Diabetes Study Group, 1998).
7. Knowler WC, Barrett Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Programe Research group N Eng J Med 2002, 346(6):393-403.
8. Abdellatif Settaf, Aziz Elimadi, Yehiya Cherrah, et al, The petroleum ether extracts of Nigella sativa seeds exert insulin sensitizing and lipid lowering action in rats. Journal. of Ethanopharmacology, 2004, Volume 94, Issue 2-3: 251-259.
9. Meral, I., Z. Yener, T. Kahraman and N. Mert, 2001. Effect of Nigella sativa on glucose concentration, lipid peroxidation, anti-oxidant defense system and liver damage in experimentally-induced diabetic rabbits. J. Vet. Med. A. Physiol. Pathol. Clin. Med., 48: 593-5990).
10. Al-Awadi, F.M. and K.A. Gumaa, 1987. Studies on the activity of individual pants of an antidiabetic plant mixture. Acta. Diabetol. Let, 24: 37-41.
11. Al-Hader, A., M. Aqel and Z. Hasan, 1993. Hypoglycemic effects of the volatile oil of Nigella sativa. International J. Pharmacognosy, 31: 96-100.).
12. El-Dakhakhny M, Mady N, Lembert N, Ammon HP.; The hypoglycemic effect of Nigella sativa oil is mediated by extrapancreatic actions. Planta Med. 2002 May; 68 (5): 465-66
13. Anas M., M Mohsin, A Mannan, M Siddiqui (2003): Hypoglycemic effect of Unani formulation (shunez karela khushk) on type-2 diabetes; Abstract book National symposium Emerging trends in Indian Medicinal Plants, 10-12 Oct 03, Lucknow, pg. 83.
14. Mehmet Kanter, Omer Coskun1, Ahmet Korkmaz2, Sukru Oter2, Effects of Nigella sativa on oxidative stress and β-cell damage in streptozotocin-induced diabetic rats, The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary BiologyVolume 279A, Issue 1, pages 685-691, July 2004
15. Kumaranayaka et al (1997). The effect of Nigella sativa oil on blood lipids. Indian J. Physiol. Pharmacol., 46: 195-201.
16. El, D. M., N. I. Mady, et al. (2000). Nigella sativa L. oil protects against induced hepatotoxicity and improves serum lipid profile in rats. Arzneimittel Forschung. Sept 50(9): 832-836.: Faculty of Medicine, Department of Pharmacology and Drug Toxicology, Alexandria University, Alexandria, 21521, Egypt.
17. El-Dakhakhny M (1963): Studies on chemical constitution of Egyptian N sativa L seeds II. The Essential oil. Planta Med, 11; 465-470.
18. Executive Summary: Standards of medical care in diabetes-2009. Diabetes Care 32: S6-S12. 2009. DOI:10.2337/dc09-S006.
19. Nathan DM, Turgeon H, Regan S. Relationship between glycated hemoglobin levels and mean glucose level over time Diabetologia 2007 50:2239-2244
20. Abdul Sattar, Allah Ditta, Muhammad Tayyib, Muhammad Ashraf. Estimation of serum lipids in albino Rats fed on palm oil and atherogenic diet and Nigella sativa. Pakistan Postgrad Med J Sep 2003; 14(3):121-4.
21. Beynen, A.C., M.B. Katan and L.F.M. Van Zutphen, 1987. Hypo-and hyperresponders: individual differences in the response of serum cholesterol concentration to changes in diet. Adv. Lipid Res., 22: 115-171.
22. Amir Hamzo Dahri, Atta Muhammad Chandiol, Ali Akbar Rahoo Rafique Ahmed Memon, Effect of Nigella sativa on serum cholesterol of albino rats, (2001) Department of Pathology, Biochemistry and Medicine Peoples Medical College Nawabshah.
23. Chaudhary et al 1996 Nigella sativaL. Oil protects against induced hepatotoxicity and improves serum lipid profile in rats. Arzneimittel Forschung, 50: 832-836.
24. Goodman and Gilman's The pharmacological basis of therapeutics
25. O'Driscoll, G. Greenand Taylor R.R. Simvastatin, an HMG Co A reductase inhibitor, improve endothelial function within one month. Circulation, 1997, 95:1126-1131.
26. Bustos C., Hernandez Presa, et al. HMG CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis Am. Coll. Cardiol.1998, 32:2057-2064.
27. Libby, P. Aikawa, Inflammation in atherosclerosis, Nature, 2002, 420:868-874
28. Hussein, O., Rosenblat, M. et al. (1997) Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to platelets. Br.J. Clin. Pharmacol., 44:77-84.
29. Nawrocki JW, Weiss SR, Davidson MH, Sprecher L, Schwartz SL, Lupien PJ, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15:678-82.
30. Pearson TA, Blair SN, et al (2002) AHA Guidelines for primary prevention of cardiovascular disease and stroke. American Heart association Science Advisory and Coordinating Committee. Circulation.106:388-391.